The so-called classic biomarkers of breast cancer (ER, PR and androgen (AR) hormone receptors, the HER2 receptor, and the Ki-67 cell proliferation marker) were the first ones to be studied and standardized and remain pillars of the clinical management of this disease, despite the emergence of new molecular candidates. This evidence concerns the gene PGR and breast carcinoma.